BEACOPP may be better than ABVD in certain Hodgkin Lymphomas
According to research presented at the American Society of Hematology 52nd Annual Meeting by Andreas Engert, MD, chair of the highly influential German Hodgkin Study Group (GHSG) of Cologne, Germany, a more intense chemotherapy regimen provides better outcomes than the current standard of care.
The HD14 trial pitted the gold standard ABVD regimen against a dose-escalated version of the BEACOPP chemotherapy regimen in patients diagnosed with early, unfavorable Hodgkin lymphoma (stages IB, IIB). The BEACOPP regimen was established by the GHSG in 1989 for the treatment of late-stage, unfavorable HL.
According to this most recent data, BEACOPP is more effective at tumor control than ABVD, but other experts countered that BEACOPP's toxic profile is too high compared to ABVD, without a corresponding survival benefit.
Read more about this at the coverage provided by Medscape.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
